Purpose This study aimed to evaluate the molecular features of clear cell adenocarcinoma (CCA) of the urinary tract and investigate its pathogenic pathways and possible actionable targets.
Materials and Methods We retrospectively collected the data of patients with CCA between January 1999 and December 2016; the data were independently reviewed by two pathologists. We selected five cases of urinary CCA, based on the clinicopathological features. We analyzed these five cases by whole exome sequencing (WES) and subsequent bioinformatics analyses to determine the mutational spectrum and possible pathogenic pathways.
Results All patients were female with a median age of 62 years. All tumors were located in the urethra and showed aggressive behavior with disease progression. WES revealed several genetic alterations, including driver gene mutations (AMER1, ARID1A, CHD4, KMT2D, KRAS, PBRM1, and PIK3R1) and mutations in other important genes with tumor-suppressive and oncogenic roles (CSMD3, KEAP1, SMARCA4, and CACNA1D). We suggest putative pathogenic pathways (chromatin remodeling pathway, mitogen-activated protein kinase signaling pathway, phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathway, and Wnt/β-catenin pathway) as candidates for targeted therapies.
Conclusion Our findings shed light on the molecular background of this extremely rare tumor with poor prognosis and can help improve treatment options.
Citations
Citations to this article as recorded by
Urethral clear cell adenocarcinoma in an adult female: A rare case report Yacob Sheiferawe Seman, Michael Teklehaimanot Abera, Fadil Nuredin Abrar, Tesfaye Kebede Legesse, Mesfin Asefa Tola, Tsiyon Nigusie Alemu Urology Case Reports.2025; 58: 102882. CrossRef
Association between CACNA1D polymorphisms and hypospadias in a southern Chinese population Ye He, Binyao Li, Xinying Zhao, Lingling Pan, Yanqing Liu, Chaoting Lan, Fuming Deng, Wen Fu, Yan Zhang, Xiaoyu Zuo Journal of Pediatric Urology.2024; 20(3): 438.e1. CrossRef
The L‐type calcium channel CaV1.3: A potential target for cancer therapy Xuerun Liu, Boqiang Shen, Jingyi Zhou, Juan Hao, Jianliu Wang Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef
Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee-Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A Kim, Kwonoh Park, Hyo Jin Lee, Jung Lim Lee, Young-Woong Won, Il Hwan Kim, Woo Kyun Bae, Kyong Hwa Park, Der-Sheng Sun, Suee Lee, Min-Young Lee, Guk Jin Lee, Sook Hee Hong, Yun Hwa Jung, Ho Jung An
Cancer Res Treat. 2020;52(1):277-283. Published online July 12, 2019
Purpose
The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early
stage.
Materials and Methods
Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected.
Results
Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤ 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence.
Conclusion
Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.
Citations
Citations to this article as recorded by
Ovarian clear cell carcinoma: open questions on the management and treatment algorithm Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli The Oncologist.2025;[Epub] CrossRef
From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer Zesi Liu, Chunli Jing, Fandou Kong Journal of Ovarian Research.2024;[Epub] CrossRef
Construction of a Prediction Model of Cancer-Specific Survival after Ovarian Clear Cell Carcinoma Surgery Mengqi Huang, Li Ling, Yanbo Liu, Yujuan Li Clinical and Experimental Obstetrics & Gynecology.2024;[Epub] CrossRef
Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery Li Shuqing, Zhu Zhiling Cancer Medicine.2023; 12(6): 6668. CrossRef
Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis Hamidreza Didar, Farah Farzaneh, Hanieh Najafiarab, Kosar Namakin, Kimiya Gohari, Ali Sheidaei, Sepehr Ramezani Current Medical Research and Opinion.2023; 39(6): 901. CrossRef
The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis Yuan Zhuang, Hua Yang Cancer Control.2023;[Epub] CrossRef
Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer Satoe Fujiwara Japanese Journal of Clinical Oncology.2023; 53(8): 664. CrossRef
Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience Yoo-Na Kim, Yun Soo Chung, Ji Hyun Lee, Eunhyang Park, Seung-Tae Lee, Sunghoon Kim, Jung-Yun Lee Journal of Gynecologic Oncology.2023;[Epub] CrossRef
Characteristics and Prognosis of Ovarian Pure Clear Cell Carcinoma: A Retrospective Experience of 136 Patients Yang Gao, Wei Ding, Pengpeng Qu Clinical and Experimental Obstetrics & Gynecology.2023;[Epub] CrossRef
A clearer view on ovarian clear cell carcinoma Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys Acta Clinica Belgica.2022; 77(4): 792. CrossRef
Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study Anastasios Tranoulis, Felicia Helena Buruiana, Bindiya Gupta, Audrey Kwong, Aarti Lakhiani, Jason Yap, Janos Balega, Kavita Singh Archives of Gynecology and Obstetrics.2022; 305(5): 1279. CrossRef
Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis Peng Chen, Chi-Yuan Zhang Frontiers in Oncology.2022;[Epub] CrossRef
Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report Abdulkarim Mohamed Farah, Shiyu Gu, Yan Jia Medicine.2022; 101(37): e30666. CrossRef
Clear cell carcinoma of the ovary: a clinical and molecular perspective Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington International Journal of Gynecological Cancer.2021; 31(4): 605. CrossRef
Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study Chenchen Zhu, Jing Zhu, Lili Qian, Hanyuan Liu, Zhen Shen, Dabao Wu, Weidong Zhao, Weihua Xiao, Ying Zhou BMC Cancer.2021;[Epub] CrossRef
The oncological outcome of the patients with ovarian clear cell cancer: Platinum-based adjuvant chemotherapy is not suitable Caner ÇAKIR, Fatih KILIÇ, Çiğdem KILIÇ, Dilek YÜKSEL, Vakkas KORKMAZ, Günsu KİMYON CÖMERT, Osman TÜRKMEN, Taner TURAN Journal of Surgery and Medicine.2021; 5(8): 1. CrossRef
Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma Qian Chen, Shu Wang, Jing-He Lang Journal of Ovarian Research.2020;[Epub] CrossRef
Purpose
We compared the predictive and prognostic values of leukocyte differential counts, systemic inflammatory (SIR) markers and cancer antigen 125 (CA-125) levels, and identified the most useful marker in patients with ovarian clear cell carcinoma (OCCC).
Materials and Methods
The study included 109 patients with OCCC who did not have any inflammatory conditions except endometriosis, and underwent primary debulking surgery between 1997 and 2012. Leukocyte differential counts (neutrophil, lymphocyte, monocyte, eosinophil, basophil, and platelet), SIR markers including neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), and platelet to lymphocyte ratio (PLR), and CA-125 levels were estimated to select potential markers for clinical outcomes.
Results
Among potential markers (neutrophil, monocyte, platelet, NLR, MLR, PLR, and CA-125 levels) selected by stepwise comparison, CA-125 levels were best at predicting advanced stage disease, suboptimal debulking and platinum-resistance (cut-off values, ≥ 46.5, ≥ 11.45, and ≥ 66.4 U/mL; accuracies, 69.4%, 78.7%, and 68.5%) while PLR ≥ 205.4 predicted noncomplete response (CR; accuracy, 71.6%) most accurately. Moreover, PLR < 205.4 was an independent factor for the reduced risk of non-CR (adjusted odds ratio, 0.17; 95% confidence interval [CI], 0.04 to 0.69), and NLR < 2.8 was a favorable factor for improved progression-free survival (PFS; adjusted hazard ratio, 0.49; 95% CI, 0.25 to 0.99) despite lack of a marker for overall survival among the potential markers.
Conclusion
CA-125 levels may be the most useful marker for predicting advanced-stage disease. Suboptimal debulking and platinum-resistance, and PLR and NLR may be most effective to predict non-CR and PFS in patients with OCCC.
Citations
Citations to this article as recorded by
Ovarian clear cell carcinoma: open questions on the management and treatment algorithm Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli The Oncologist.2025;[Epub] CrossRef
Correlation between pre-operative platelets count and serum cancer antigen-125 level in epithelial ovarian carcer Justina Omoikhefe Alegbeleye, Celestine Osita John Indian Journal of Obstetrics and Gynecology Research.2024; 11(1): 17. CrossRef
Trends in survival of ovarian clear cell carcinoma patients from 2000 to 2015 Bing-Qian Tian, Shu-Wen Wang, Jing-Ying Xu, San-Gang Wu, Juan Zhou Frontiers in Oncology.2024;[Epub] CrossRef
Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line Jaime Espinós, José Manuel Aramendía, Antonio González-Martín, Marta Santisteban, Luisa Sánchez, Ángel Vizcay, José Ángel Mínguez, Juan Luis Alcázar Clinical and Translational Oncology.2024; 26(12): 3211. CrossRef
The prognostic and clinical value of neutrophil-to-lymphocyte ratio (NLR) in ovarian cancer: A systematic review and meta-analysis Zihan Zhang, Jinghe Lang Journal of Medical Biochemistry.2024; 43(4): 323. CrossRef
Combined use of CA125, neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors Ke Huang, Shengjie Xu, Jiatong Wang, Lili Ge, Juan Xu, Xuemei Jia Journal of Ovarian Research.2023;[Epub] CrossRef
Independent predictive value of blood inflammatory composite markers in ovarian cancer: recent clinical evidence and perspective focusing on NLR and PLR Chuan-long Zhang, Xiao-chen Jiang, Yi Li, Xue Pan, Meng-qi Gao, Yan Chen, Bo Pang Journal of Ovarian Research.2023;[Epub] CrossRef
Trends in Systemic Inflammatory Reaction (SIR) during Paclitaxel and Carboplatin Chemotherapy in Women Suffering from Epithelial Ovarian Cancer Michal Mleko, Elzbieta Pluta, Kazimierz Pitynski, Maciej Bodzek, Andrzej Kałamacki, Dorota Kiprian, Tomasz Banas Cancers.2023; 15(14): 3607. CrossRef
Research Progress of the Relationship between Peripheral Blood Indexes and the Diagnosis, Treatment and Prognosis of Ovarian Cancer 洁 严 Advances in Clinical Medicine.2023; 13(11): 17362. CrossRef
Diagnostic significance of neutrophil to lymphocyte ratio in endometriosis: a systematic review and meta-analysis Fatemeh Tabatabaei, Hossein Tahernia, Arshin Ghaedi, Aida Bazrgar, Shokoufeh Khanzadeh BMC Women's Health.2023;[Epub] CrossRef
Comparison of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio levels in ovarian cyst among epithelial ovarian cancer patients at RSUP H. Adam Malik Medan, Indonesia Mega Sari Dewi, Roy Yustin Simanjuntak, Letta Sari Lintang, Muhammad Fahdhy, Deri Edianto, Makmur Sitepu Majalah Obstetri & Ginekologi.2023; 31(3): 117. CrossRef
The role of IL-6/JAK2/STAT3 signaling pathway in cancers Bei Huang, Xiaoling Lang, Xihong Li Frontiers in Oncology.2022;[Epub] CrossRef
Evaluation of CA-125 Biomarker in Acute Appendicitis Patients: Correlation with Clinical Symptoms and Lab Results Mojtaba Ahmadinejad, Seyed A. Hashemi, Alireza Shirzadi, Ali Soltanian, Jafar Ashrafi, Kourosh Kabir, Mahla Alizadeh The Open Public Health Journal.2021; 14(1): 162. CrossRef
The Use of Platelet/Lymphocyte Ratio and Cancer Antigen 125 Combined with Magnetic Resonance Diffusion-Weighted Imaging in Diagnosis of Recurrent Ovarian Cancer and Neuropathic Pain Na Wang, Cuiping Li, Yujie Yang, Yu Guan, Fengjiao Wang, Yan Wang, Wei Zhao World Neurosurgery.2021; 149: 502. CrossRef
Role of Systemic Inflammatory Reaction in Female Genital Organ Malignancies – State of the Art Michal Mleko, Kazimierz Pitynski, Elzbieta Pluta, Aleksandra Czerw, Katarzyna Sygit, Beata Karakiewicz, Tomasz Banas Cancer Management and Research.2021; Volume 13: 5491. CrossRef
The diagnostic value of the combination of hemoglobin, CA199, CA125, and HE4 in endometriosis Ting Chen, Jia‐Ling Wei, Ting Leng, Fei Gao, Shun‐yu Hou Journal of Clinical Laboratory Analysis.2021;[Epub] CrossRef
Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer Carolina Maria Sassu, Innocenza Palaia, Serena Maria Boccia, Giuseppe Caruso, Giorgia Perniola, Federica Tomao, Violante Di Donato, Angela Musella, Ludovico Muzii International Journal of Molecular Sciences.2021; 22(24): 13650. CrossRef
Prognostic significance of preoperative circulating FAR and FCI scores in patients with ovarian cancer Huige Wang, Yanjun Shen, Xiaoyan Ding, Yongfen Ding, Ling Cheng, Juan Lai Clinica Chimica Acta.2020; 509: 252. CrossRef
Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications Wei Chen, Siyuan Zhong, Boer Shan, Shuling Zhou, Xiaohua Wu, Huijuan Yang, Shuang Ye Journal of Ovarian Research.2020;[Epub] CrossRef
Preoperative neutrophil-to-lymphocyte ratio predicts 30 day postoperative morbidity and survival after primary surgery for ovarian cancer Julie My Van Nguyen, Sarah Elizabeth Ferguson, Marcus Q Bernardini, Taymaa May, Stephane Laframboise, Liat Hogen, Geneviève Bouchard-Fortier International Journal of Gynecological Cancer.2020; 30(9): 1378. CrossRef
Sarcopenia: Clinical implications in ovarian cancer, diagnosis, etiology, and management Aeran Seol, Se Ik Kim, Yong Sang Song Sports Medicine and Health Science.2020; 2(4): 202. CrossRef
Associations between Blood Cell Profiles and Primary Open-Angle Glaucoma: A Retrospective Case-Control Study Binghua Tang, Shengjie Li, Jianping Han, Wenjun Cao, Xinghuai Sun Ophthalmic Research.2020; 63(4): 413. CrossRef
Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma Kosuke Yoshida, Nobuhisa Yoshikawa, Akira Shirakawa, Kaoru Niimi, Shiro Suzuki, Hiroaki Kajiyama, Fumitaka Kikkawa Journal of Gynecologic Oncology.2019;[Epub] CrossRef
Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer Jie-Ping Chen, Qi-Dan Huang, Ting Wan, Hua Tu, Hai-Feng Gu, Jun-Ya Cao, Ji-Hong Liu Journal of Ovarian Research.2019;[Epub] CrossRef
Pretreatment platelet‐to‐lymphocyte ratio is associated with the response to first‐line chemotherapy and survival in patients with metastatic gastric cancer Jin Wang, Jinglei Qu, Zhi Li, Xiaofang Che, Jing Liu, Yuee Teng, Bo Jin, Mingfang Zhao, Yunpeng Liu, Xiujuan Qu Journal of Clinical Laboratory Analysis.2018;[Epub] CrossRef
Comparison of clinical utility between neutrophil count and neutrophil–lymphocyte ratio in patients with ovarian cancer: a single institutional experience and a literature review Naoko Komura, Seiji Mabuchi, Eriko Yokoi, Katsumi Kozasa, Hiromasa Kuroda, Tomoyuki Sasano, Yuri Matsumoto, Tadashi Kimura International Journal of Clinical Oncology.2018; 23(1): 104. CrossRef
Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies Zhe Zhao, Xinrui Zhao, Jingjing Lu, Jing Xue, Peishu Liu, Hongluan Mao Archives of Gynecology and Obstetrics.2018; 297(4): 849. CrossRef
The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis Joanna L. Sylman, Annachiara Mitrugno, Michelle Atallah, Garth W. Tormoen, Joseph J. Shatzel, Samuel Tassi Yunga, Todd H. Wagner, John T. Leppert, Parag Mallick, Owen J. T. McCarty Frontiers in Oncology.2018;[Epub] CrossRef
Analysis of preoperative blood platelet parameters in terms of diversity of epithelial ovarian cancer Katarzyna Bednarska, Ewa Król, Ewa Głowacka, Hanna Romanowicz, Krzysztof Szyłło, Magdalena Klink, Zofia Sułowska, Marek Nowak Medicine.2018; 97(12): e0180. CrossRef
Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24) Alberto Farolfi, Micaela Petrone, Emanuela Scarpi, Valentina Gallà, Filippo Greco, Claudia Casanova, Lucia Longo, Gennaro Cormio, Michele Orditura, Alessandra Bologna, Laura Zavallone, Jole Ventriglia, Elisena Franzese, Vera Loizzi, Donatella Giardina, Ev Targeted Oncology.2018; 13(4): 469. CrossRef
Prognostic Value of Serum CA19-9 and Perioperative CA-125 Levels in Ovarian Clear Cell Carcinoma Jun Zhu, Long Jiang, Hao Wen, Rui Bi, Xiaohua Wu, Xingzhu Ju International Journal of Gynecological Cancer.2018; 28(6): 1108. CrossRef
Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis Gaowen Chen, Lin Zhu, Yulu Yang, Yusheng Long, Xiangyuan Li, Yifeng Wang Technology in Cancer Research & Treatment.2018;[Epub] CrossRef
Preoperative multiplication of neutrophil and monocyte counts as a prognostic factor in epithelial ovarian cancer E Sun Paik, Minhee Shim, Hyun Jin Choi, Yoo-Young Lee, Tae-Joong Kim, Chel Hun Choi, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae Cancer Biomarkers.2017; 17(4): 419. CrossRef
Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis Josee-Lyne Ethier, Danielle N Desautels, Arnoud J Templeton, Amit Oza, Eitan Amir, Stephanie Lheureux Gynecologic Oncology.2017; 145(3): 584. CrossRef
The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer Anastasia Prodromidou, Panagiotis Andreakos, Charalampos Kazakos, Dimitrios Eftimios Vlachos, Despina Perrea, Vasilios Pergialiotis Inflammation Research.2017; 66(6): 467. CrossRef
The value of the combination of hemoglobin, albumin, lymphocyte and platelet in predicting platinum-based chemoradiotherapy response in male patients with esophageal squamous cell carcinoma Lihong Cong, Likuan Hu International Immunopharmacology.2017; 46: 75. CrossRef
Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis Yanlin Luo, Hee Seung Kim, Miseon Kim, Maria Lee, Yong Sang Song Journal of Gynecologic Oncology.2017;[Epub] CrossRef
Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway Boyun Kim, Hee Seung Kim, Soochi Kim, Guy Haegeman, Benjamin K. Tsang, Danny N. Dhanasekaran, Yong Sang Song Cancer Research and Treatment.2017; 49(2): 338. CrossRef
Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma Hongwei Zhang, Jiaqi Lu, Yingying Lu, Jiayi Zhou, Zehua Wang, Haiou Liu, Congjian Xu, Renato Franco PLOS ONE.2017; 12(5): e0177520. CrossRef
Neutrophil-to-Lymphocyte Ratio Is a Potential Prognostic Biomarker in Patients with Ovarian Cancer: A Meta-Analysis Shubo Chen, Liu Zhang, Guangyue Yan, Sijin Cheng, Abdel Hamid Fathy, Nana Yan, Yongzhao Zhao BioMed Research International.2017; 2017: 1. CrossRef
Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients Quan Zhou, Li Hong, Man-Zhen Zuo, Ze He Oncotarget.2017; 8(40): 68938. CrossRef
Predictive value of systematic inflammatory response biomarkers (NLR, LMR, PLR) in patients with ovarian cancer. Urszula Rychlik, Ewa Wójcik, Jadwiga Tarapacz, Katarzyna Brandys, Zofia Stasik, Beata Kala, Jan K. Kulpa, Wiktor Szatkowski, Paweł Blecharz, Jerzy Jakubowicz Diagnostyka Laboratoryjna.2017; 53(3): 139. CrossRef
Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy Yi Miao, Qin Yan, Shuangdi Li, Bilan Li, Youji Feng Cancer Biomarkers.2016; 17(1): 33. CrossRef
Serum carbohydrate antigen 125 concentration as a superior predictor for serosal effusion at diagnosis and a prognostic factor in diffuse large B-cell lymphoma Jia-Zhu Wu, Tian Tian, Ying Huang, Jin-Hua Liang, Yi Miao, Li Wang, Ji Xu, Xiao-Yan Qu, Lei Fan, Jian-Yong Li, Wei Xu Cancer Biomarkers.2016; 17(2): 205. CrossRef
The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study Huimin Bai, Guisha Sha, Meizhu Xiao, Huiqiao Gao, Dongyan Cao, Jiaxin Yang, Jie Chen, Yue Wang, Zhenyu Zhang, Keng Shen Oncotarget.2016; 7(13): 15566. CrossRef
Infrequent Expression of the Cancer-Testis Antigen, PASD1, in Ovarian Cancer Ghazala Khan, Suzanne E. Brooks, Ken I. Mills, Barbara-Ann Guinn Biomarkers in Cancer.2015; 7: BIC.S28378. CrossRef